公司资料
Dyne Therapeutics 股价、新闻与催化剂
- 股票代码:
- DYN
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
26.10 USD (+0.46%)
收盘价
最后更新: 2026年8月21日
2.85B USD
市值
股价为何变动
The latest company update was “Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)”. DYN changed 0.46% and closed at $26.10 on Aug 21, 2026, indicating a relatively limited closing-price reaction to this company update.
公司概览
Oligonucleotide Therapeutics
Dyne Therapeutics develops targeted oligonucleotide medicines for genetically driven muscle diseases. Its FORCE platform links therapeutic payloads to antibodies intended to improve delivery into muscle tissue.
Duchenne Muscular Dystrophy
Z-rostudirsen is designed for patients with Duchenne muscular dystrophy amenable to exon 51 skipping. The candidate has completed the registrational portion of the DELIVER program, and Dyne is preparing it for regulatory submission and commercialization.
Myotonic Dystrophy
Z-basivarsen targets toxic DMPK RNA in myotonic dystrophy type 1. It is being evaluated in the Phase 1/2 ACHIEVE study and the global confirmatory Phase 3 HARMONIA trial.
未来催化剂
- BLA submission for z-rostudirsen in the second quarter of 2026.
- Completion of enrollment in the registrational ACHIEVE expansion cohort for z-basivarsen in the second quarter of 2026.
- Potential U.S. launch of z-rostudirsen in the first quarter of 2027, subject to approval.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。